XVIVOS logo

Xvivo Perfusion BATS-CHIXE:XVIVOS Stock Report

Last Price

SEK 448.75

Market Cap

SEK 15.5b

7D

0%

1Y

36.0%

Updated

10 Jan, 2025

Data

Company Financials +

Xvivo Perfusion AB (publ)

BATS-CHIXE:XVIVOS Stock Report

Market Cap: SEK 15.5b

XVIVOS Stock Overview

A medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. More details

XVIVOS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance4/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Xvivo Perfusion AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Xvivo Perfusion
Historical stock prices
Current Share PriceSEK 448.75
52 Week HighSEK 503.50
52 Week LowSEK 448.75
Beta2.14
1 Month Change0%
3 Month Changen/a
1 Year Change35.98%
3 Year Change69.34%
5 Year Change139.97%
Change since IPO160.14%

Recent News & Updates

Recent updates

Shareholder Returns

XVIVOSGB Medical EquipmentGB Market
7D0%1.0%-0.3%
1Y36.0%-10.0%4.9%

Return vs Industry: XVIVOS exceeded the UK Medical Equipment industry which returned -8% over the past year.

Return vs Market: XVIVOS exceeded the UK Market which returned 6.6% over the past year.

Price Volatility

Is XVIVOS's price volatile compared to industry and market?
XVIVOS volatility
XVIVOS Average Weekly Movementn/a
Medical Equipment Industry Average Movement6.4%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.8%
10% least volatile stocks in GB Market2.6%

Stable Share Price: XVIVOS's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine XVIVOS's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998161Christoffer Rosenbladwww.xvivogroup.com

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment.

Xvivo Perfusion AB (publ) Fundamentals Summary

How do Xvivo Perfusion's earnings and revenue compare to its market cap?
XVIVOS fundamental statistics
Market capSEK 15.54b
Earnings (TTM)SEK 204.27m
Revenue (TTM)SEK 750.59m

76.1x

P/E Ratio

20.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
XVIVOS income statement (TTM)
RevenueSEK 750.59m
Cost of RevenueSEK 192.08m
Gross ProfitSEK 558.52m
Other ExpensesSEK 354.25m
EarningsSEK 204.27m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 28, 2025

Earnings per share (EPS)6.48
Gross Margin74.41%
Net Profit Margin27.21%
Debt/Equity Ratio0%

How did XVIVOS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 11:07
End of Day Share Price 2024/11/04 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xvivo Perfusion AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dylan van HaaftenBryan Garnier & Co
Maria Vara FernándezBryan Garnier & Co
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB